



## PAVIA Implementation Progress: ETHIOPIA

#### **COUNTRY SPECIFIC ACHIEVEMENTS & CLOSING REPORTS**

Asnakech Alemu

**Product Safety Director** 



### **Presentation Outline**

- Key PAVIA achievements
- General PV achievements
- Best practices for other countries
- Closing plans
- Plans for sustainability post-PAVIA
  - Country PV Linkages with other PV stakeholders
  - Cascading of PV activities
  - Plans for continuation of PV trainings, and capacity building
  - Plans for continued strengthening of PV regulatory and policy frameworks



Plans for sustainability of the PV triangle







Significant improvement in ADE reporting from TICs has been observed : Which was achieved by improved


### 1. aDSM sensitization meetings, trainings








#### In august 50/64 TICs, report was shared with key stakeholders.









#### Key PAVIA achievements...

#### **Globally Shared Reports**

3.Since the start of the project total 654 reports received from TICs (including through RHBs) up to

#### December 2022

#### **Only 41** reports received before the start of the PAVIA project







### Key PAVIA achievements...

## PARTIACO Vigilance Africa

#### **Globally Shared Report...**







0.0-1	https://vigifiow.who-	umc.org/searchicsr	s Q Searc	ch		LAS				VigiFlow - 5
0 8 =	nttps://vigitiow.wite	VigiFlov	v - ET Food, Medicine & Healthcare Admin and Control Authority							A
			COLUMN A DESCRIPTION OF		<b>T</b> Filter	E ZP				
() Import	• Export VigiLyze			Page 1 of 14	196 2 1	2 3 4		@ Export While WR		
ports match you	ur search with 1 filters appli	ed		Drug name (WHODrug) Inital	Latest	Status	SR + New AEFI   Import	@ Expoir (Mareney)		
ique id 🛊	Delegated to organisation	Initials   Datepf birth	Reaction / event (MedDRA)	receive	date					
980	ET Food, Medicine & Healthcare Admin and	MS		Bedaquiline, 2002202 Clofazimine, Linezolid						
C	ET Food, Medicine &	G.B	5°	Clofazimine, Linezolid 200220	23 20022023	3 Open	elected - 29911 reports match yo			
	Healthcare Admin and Control Authority ET Food, Medicine &	vinet	Hypersensitivity reaction	150220	23 15022023	3 Open				
179	Healthcare Admin and Control Authority		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	COVID-19 vaccine 060220	23 06022023	3 Open	Worldwide unique id 🖨	Delegated to	Initials 🗘	Date of - F
A- 43206730-66XY4	ET Food, Medicine & Healthcare Admin and Control Authority	Tesfanesh 300919		Janssen .		h		organisation		birth
	ET Food, Medicane & Healthcare Admin and	iod, Medicine & Miss 20111994 Incare Admin and		Dihydroartemisinin 060220	23 0602202	3 Open				ing a construction of the second s
168 E	Control Authority ET Food, Mediane & Healthcare Admin and	A patient	Kounis syndrome, Fatigue, Coronary spasm, Injection sile redness, Pseudoallergic reaction, Chest lightness, Headache, Burning sensation, Urticaria, Cardiac troponi		23 0202202	3 Open	ET-EFDA-300031980	ET Food, Medicine &	- M.S	
	Control Authority		Tincreased, Left vertricular hypertrophy, Anaphylactoid reaction, Dizziness, Myocardial injury, Bronchospasm					Healthcare Admin and		
167	ET Food, Medicine & Healthosre Admin and Control Authority	semira 0112200	00	010220	0102202	3 Open		Control Authority		
68	ET Food, Medicine & Healthcare Admin and	150219	97		3001202	3 Open	ET-EFDA-300031981	ET Food, Medicine &	G.B	
62	Control Authority ET Food, Medicine & Healthcare Admin and Control Authority	AS 0101200	06 Injection site pain, Injection site redness, Injection site swelling, Injection site numbress	Pfizer BioNTech 280120 COVID-19 vaccine	23 2801202	13 Open		Healthcare Admin and Control Authority		
e s	FT Food Medicine &	HTA 0101200	15. Intertion sile name intertion sile redness. Intertion sile numbrass. Fauer	Pfizer BioNTech 28012	173 2801202	ET-EFDA-300031979	ET Food, Medicine &	zinet		
					• 4 0 1	k 7 m		Healthcare Admin and	- HIEL	
								Control Authority		the second s



# 4. Strengthen Collaboration Work with EFDA, NTP and AHRI)

- PAVIA strengthen collaboration and work together of EFDA, NTP and AHRI with improver our Pharmacovigillance system.
- Triangle Members: NTP,AHRI,PV Center, PAVIA CO.

EDC

- Meeting regularity = Planned monthly but due to varied schedules regularity not maintained .
- But beyond the regular meeting triangle members collaborate in implementing planned activities. e.g Trainings, SS ,development of guidelines, SOPs etc...
- Integration of aDSM topics in the general pharmacovigilance and pharmaceuticals, PMDT & supply chain management
- Strengthen collaboration with NTP and AHRI contributed to improved reporting of ADEs.



### Key PAVIA achievements...

- 5. Investigation of reported MDR TB drugs SAE cases
- 6. Additional reporting methods introduced ,Decentralization of PV center and focal persons trained on:
- E-reporting: <u>www.fmhaca.gov.et</u>, services link, e-Reporting of ADR
- MedSafety mobile apps,
- Mail reporting system: <u>pharmacovigilance@efda.gov.et</u>
- □ RMP/PSURS/ICSRs from MAH
- previously existing ADE reporting tools:
  - Yellow Form (ADE reporting form)/hard copy, manual/
  - AEFI Reporting Form / hard copy, manual/
  - ✓ AE Line listing form / hard copy, manual/
- ADE was incorporated in the MDR TB Tracker (case-based EMR for DR-TB) which is developed by NTP.







#### 7. Dissemination of aDSM data analysis result (different

stakeholders including higher officials involved)


















### 9. Established PV stakeholder platform and aDSM Committee





aco Vigilanc Africa






## General Key achievements




- The National PV road map was Approved
- The National PV directive was Approved
  - Establish a mandatory requirement of QPPV for MAHs
  - Incorporate Mandatory performance and funding of PASS
  - Set out timelines for submission of PSUR, ISCRs, RMP in line with International Standards,
- Patient reporting guideline was developed
- Stakeholder engagement for PV activities ToR was approved
- Integration of PV training to national CPD course



### Key achievements...



# PV Policy, law and regulations





#### Rationale:

Need for a strong drugs *administration and regulation* to maintain public health and safety:

To ensure SEQ + RU





Systems, structure and stakeholder coordination...


- New EFDA structure was approved by civil service commission on June 2022.
- Under this New EFDA structure PV and Post marketing surveillance Directorate will be established.
- EFDA branch offices will be expanded from 6 to 11 branches office and under each branch office PV and Post marketing surveillance desk will be established.
- Staff deployment is on progress
- PV stakeholder coordination plate form was established











EDCTP \*\*\*

EFDA



### Key achievements...

#### PAC re-established with revised ToR

- Broadening its scope to all medicine
- Inclusion of relevant experts
- Revision of TOR
- □ Issuing nomination letter

#### EFDA is working for Maturity level 3

#### Necessary QMS documents were prepared:

- Legal documents such as pharmacovigilance directive
- PV guidelines
- Quality Manual
- SOP
- Checklist



Records were developed



## DSM supportive Research in collaboration with AHRI



#### **Research:**

#### Title and Methods

- Performance of aDSM for PV strengthening in Ethiopia; Experience assessment from MDR-TB management program
  - mixed method involving both quantitative and qualitative
  - Data abstraction tools for patient chart review *plus* questionnaire, therefore
  - level of aDSM performance, prevalence of adverse events (AEs), level of AE detection and management and factors affecting aDSM performance are assessed
  - Involving >10 TICs

#### Progress, achievements

- Data collected from >1300 Patients' charts
- Data cleaning in progress
- Manuscript writing will be started end of Feb, 2023.

#### **Systematic Review:**

'Safety and treatment outcome of bedaquiline and delamanid containing regimens in the treatment of MDR/XDR TB among HIV co-infected patients: a systematic review and planned meta-analysis'

Objective - assess safety risks in TB-HIV co-infected management when new anti-Tb drugs are used

Progress:

- Prospero registered
- Data mining is completed, papers screened, selected
- Drafting the first version





### Best practices for other countries

- Development of PV Roadmap
- Legal framework e.g. The National PV directive was Approved
- Strengthen collaboration with NTP and AHRI contributed to improved reporting of ADEs.
- Expansion of health care workers training on PV
  - More than 4500 Health care proffesionals trained on PV
- Preparation of procedures related to PV( Stakeholders ToR, SOP related to aDSM, PV road map...)
- Structural re-arrangement of PV function :-

New EFDA structure was approved by civil service commission on June 2022.-Under this New EFDA structure PV and Post marketing surveillance Directorate will be established.

- Developed PV training manual, indorsed as CPD course
- AEFI training manual








## Closing plans:

• Implementation of prepared PV related procedures



- PHP integration to safety monitoring
- Expansion of the best practices to other public health program medicines and other medicines(Chronic, infectious...)
- Creation of model health institutions taking the TICs as model
- Keep in update of safety reports through the established systems



including TICs and focal persons

## Plans for sustainability post-PAVIA

- PARVIA PhArmaco Vigilance Africa
- Country PV Linkages with other PV stakeholders. Will this continue after PAVIA. yes,
  - Developed stakeholders engagement ToR and approved by stakeholders
  - TORS describes who are stakeholders, how and when to meet, responsibilities
- Cascading of PV activities. Will this continue after PAVIA. yes,
  - PV has its own structure staffs and budget
  - It has its own annual and monthly plan/deliverables
  - Provided many capacity building activities,
    - continuous onsite support and developing knowledge and skill transfer among health professionals



## Jans for sustainability post-PAVIA

- Plans for continuation of PV trainings, and capacity building.
  - Developed PV training manual and included in country CPD course , provided by EPA
  - Standard AEFI training manual was developed
- Plans for continued strengthening of PV regulatory and policy frameworks. Will this continue after PAVIA. If yes, how?
  - Revision of PV guideline
  - Work to WHO maturity level 3
- Plans for sustainability of the PV triangle.
  - This will be in larger scale, PV stakeholders as included in ToR
  - Working on other PV research activities (AHRI)
  - Work with PHP to improve AE reporting rate



• AEFI system assessment, ... Integrate AE reporting with program data reporting







### THANK YOU

## አመሰግናለሁ!!!

